Table 6.

Comparison of composite clinical endpoints between two groups of patients.

Group	n	Endpoints		Adverse reactions
		Cardiovascular events	Worsening heart failure	Dizziness	Impaired kidney function	Hyperkalemia	Hypotension	Total
Control	39	7 (17.95)	6 (15.38)	3 (7.69)	1 (2.56)	0 (0.00)	1 (2.56)	5 (12.81)
Entresto	39	2 (5.13)	1 (2.56)	1 (2.56)	1 (2.56)	1 (2.56)	1 (2.56)	4 (10.24)
χ 2		7.562	6.654					2.562
P		0.013	0.025					0.078